Clinical trial
Ribavirin, Its Dosing Regime
NCT00484328 · Maastricht University Medical Center, Other · Completed
Key facts
| NCT number | NCT00484328 |
|---|---|
| Title | Ribavirin, Its Dosing Regime |
| Official title | Ribavirin, Its Dosing Regime |
| Acronym | Ribados |
| Lead sponsor | Maastricht University Medical Center, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Ribavirin |
| Enrollment | 15 |
| Start date | Jul 1, 2007 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Jun 8, 2007 |
| Last update posted | Jan 9, 2018 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: